Equities Analysts Issue Forecasts for FATE FY2025 Earnings

Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Investment analysts at Cantor Fitzgerald boosted their FY2025 earnings estimates for shares of Fate Therapeutics in a report released on Tuesday, March 18th. Cantor Fitzgerald analyst L. Watsek now expects that the biopharmaceutical company will post earnings of ($1.20) per share for the year, up from their previous forecast of ($1.67). The consensus estimate for Fate Therapeutics' current full-year earnings is ($1.63) per share.

Fate Therapeutics (NASDAQ:FATE - Get Free Report) last posted its quarterly earnings data on Wednesday, March 5th. The biopharmaceutical company reported ($0.31) EPS for the quarter, topping analysts' consensus estimates of ($0.44) by $0.13. The firm had revenue of $1.86 million for the quarter, compared to analyst estimates of $1.57 million. Fate Therapeutics had a negative return on equity of 45.88% and a negative net margin of 1,325.43%.

FATE has been the topic of several other reports. Wells Fargo & Company decreased their target price on shares of Fate Therapeutics from $5.00 to $4.00 and set an "equal weight" rating on the stock in a report on Thursday, March 6th. Stifel Nicolaus decreased their price objective on shares of Fate Therapeutics from $5.00 to $3.00 and set a "hold" rating on the stock in a research note on Thursday, March 6th. Needham & Company LLC restated a "hold" rating on shares of Fate Therapeutics in a research report on Thursday, March 6th. StockNews.com downgraded Fate Therapeutics from a "hold" rating to a "sell" rating in a report on Tuesday, March 11th. Finally, Wedbush reiterated a "neutral" rating and issued a $5.00 price target on shares of Fate Therapeutics in a research note on Thursday, March 6th. One analyst has rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $5.50.

Remove Ads

Fate Therapeutics Stock Performance

Shares of NASDAQ FATE traded up $0.03 during mid-day trading on Thursday, reaching $0.94. The company had a trading volume of 1,558,131 shares, compared to its average volume of 2,260,779. The firm has a market cap of $107.81 million, a price-to-earnings ratio of -0.57 and a beta of 2.26. The business's 50-day simple moving average is $1.21 and its 200 day simple moving average is $2.14. Fate Therapeutics has a one year low of $0.87 and a one year high of $7.65.

Institutional Investors Weigh In On Fate Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its stake in shares of Fate Therapeutics by 18.2% during the third quarter. JPMorgan Chase & Co. now owns 1,837,304 shares of the biopharmaceutical company's stock valued at $6,431,000 after purchasing an additional 283,080 shares in the last quarter. Barclays PLC raised its holdings in Fate Therapeutics by 245.3% in the 3rd quarter. Barclays PLC now owns 424,277 shares of the biopharmaceutical company's stock valued at $1,485,000 after buying an additional 301,389 shares during the last quarter. SG Americas Securities LLC boosted its position in Fate Therapeutics by 30.6% during the 4th quarter. SG Americas Securities LLC now owns 44,874 shares of the biopharmaceutical company's stock worth $74,000 after buying an additional 10,511 shares during the period. Walleye Capital LLC grew its holdings in Fate Therapeutics by 263.5% during the 3rd quarter. Walleye Capital LLC now owns 67,609 shares of the biopharmaceutical company's stock worth $237,000 after acquiring an additional 49,009 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Fate Therapeutics by 0.5% in the 3rd quarter. Geode Capital Management LLC now owns 2,258,246 shares of the biopharmaceutical company's stock valued at $7,905,000 after acquiring an additional 10,863 shares during the period. Institutional investors own 97.54% of the company's stock.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.